Kaplan-Meier estimates of OS according to integrated-risk status, based on cytogenetic and mutational classification, in CD25^POS versus CD25^NEG patients. Data are shown for the OS of patients with intermediate risk (A; CD25^NEG n = 108, CD25^POS n = 30) or (B) with unfavorable (high) risk (CD25^NEG n = 97, CD25^POS n = 43). (C) The composite shows that OS in CD25^POS intermediate risk (IR) patients was not significantly different from that in CD25^POS or CD25^NEG high-risk (HR) patients (P = .091). Solid lines depict CD25^NEG patients, and dashed lines depict CD25^POS patients. Only 1 CD25^POS patient was low risk (LR).